Factor V Leiden: Association with venous thromboembolism in pregnancy and screening issues

British Journal of Biomedical Science

Volumn 61, Issue 3, 2004, Pages 157-164

  Harvey, D ^a   Lowe, G M ^b  

^a ARROWE PARK HOSPITAL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Factor V; Pregnancy; Screening; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8A; PLASMA PROTEIN; THROMBIN;

ANTICOAGULATION; BLOOD CLOTTING; COMPLEX FORMATION; CROSS LINKING; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HYPERCOAGULABILITY; POLYMERIZATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 4644219528     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2004.11732662     Document Type: Review

References (47)

1. Hoffbrand AV, Petitt JE, Moss PAH. Essential haematology (4th edn). London: Blackwell Science, 2001.
2. Mehta A, Hoffbrand V. Haematology at a glance. New York: Blackwell Science, 2000.
3. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-32.
4. Axelsson F, Rosén S. APC resistance (Haemostasis Monograph 9). Instrumentation Laboratory, UK. 1997.
5. Cooper DN, Krawczak M. Venous thrombosis: from genes to clinical medicine. Oxford: BIOS Scientific, 1997.
6. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 296(50): 31869-80.
7. Hoffbrand AV, Lewis SM, Tuddenham, EGD. Postgraduate haematology (4th edn). Oxford: Butterworth Heinemann, 1999.
8. Kalafatis M, Mann, KG. Factor V: Jeckyll and Mr Hyde. Adv Exp Med Biol 2001; 489: 31-43.
9. Mazza JJ. Manual of clinical haematology (3rd edn). London: Lyppincott Williams and Wilkins, 2002.
10. R506Q by activated protein C. J Biol Chem 1995;270:21158-66.
11. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of Factor V. Blood 1999; 93: 2552-8.
12. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 1004-8.
13. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
14. 506-factor V. Blood 1995; 85: 3405-11.
15. Ridker PM, Miletich J. Ethnic distribution of factor V Leiden in 4047 males and females. Implication in venous thromboembolism screening. JAMA 1997; 277(16): 1305-7.
16. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
17. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
18. Rosendaal FR, Koster T, Vandenbroucke JP Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
19. Walker ID. Guidelines on the investigation and management of thrombophilia: The British Committee for Standards in Haematology. J Clin Pathol 1990; 43: 703-9.
20. Dahlbäck B. Are we ready for FV Leiden screening? Lancet 1996; 347:1346-7.
21. Kapiotis S, Quenhenberger P, Jilma B, Handler S, Pabinger-Fasching I, Mannhalter C. Improved characteristic of APC-resistance assay. Am J Clin Pathol 1996; 106: 588-93.
22. Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q506 mutation. Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-9.
23. Cooper PC, Cooper SM, Smith JM, Kitchen S, Makris M. Evaluation of the Roche light cycler: a simple and rapid method for the detection of Factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction. Blood Coag Fibrinolysis 1999; 14: 499-503.
24. Mitterer M, Lanthaler AJ, Mair W, Giacomuzzi K, Coser P. Simultaneous detection of FV Q506 and prothrombin 20210A variation by allele-specific PCR. Haematologica 1999; 84: 204-7
25. Clark P, Brennand J, Conkie J, McCall F, Geer I, Walker I. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70.
26. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-82.
27. Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995; 172: 147-50.
28. Kjellberg U, Anderson NE, Rosen S. APC resistance and other hemostatic variables during pregnancy and puerperium. Thromb Haemost 1999; 81: 527-31.
29. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology 2002; 353-68.
30. Koster T, Rosendaal FR, De Ronde H. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
31. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335(2): 108-14.
32. Lindqvist P. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-9.
33. Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
34. Dizon-Townson D, Nelson LM, Jang H, Vamer MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997; 176(4): 883-6.
35. Hirsch DR, Mikkola KM, Marks PW. Pulmonary embolism and deep vein thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.
36. Grandone E, Margaglione M, Colaizzo D et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179: 1324-8.
37. Gerhardt A, Scharf RE, Beckman MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
38. Bokawera MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
39. Hough RE, Makris M, Preston FE. Pregnancy in women with thrombophilia: incidence of thrombosis and pregnancy outcome. Br J Haematol 1996; 93 (Suppl 1).
40. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptive. Am J Obstet Gynecol 1995; 173: 210-3.
41. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87(5): 791-5.
42. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
43. McColl MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy-associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.
44. Walker ID, Greaves M, Preston FE. Guideline: investigation and management of heritable thrombophilia. British Committee for Standards in Haematology. Br J Haematol 2001; 114: 512-28.
45. Clark P, Twaddle S, Walker ID, Scott L, Greer IA. Cost-effectiveness of screening for factor V Leiden mutation in pregnant women. Lancet 2002; 359: 1919-20.
46. Walker ID. Thrombophilia in pregnancy. J Clin Pathol 2000; 53: 573-80.
47. Sibai BM. Thrombophilias and adverse outcomes of pregnancy - what should a clinician do? N Engl J Med 1999; 340: 50-1.